

Richard W Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2591690/publications.pdf>

Version: 2024-02-01

27
papers

4,985
citations

331538

21
h-index

526166

27
g-index

27
all docs

27
docs citations

27
times ranked

3441
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2000, 343, 1586-1593.	13.9	1,776
2	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. <i>Arthritis and Rheumatism</i> , 2002, 46, 1443-1450.	6.7	664
3	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 963-974.	5.2	348
4	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 1194-1203.	6.7	312
5	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 2002, 46, 2410-2420.	6.7	272
6	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2445-2454.	6.7	252
7	Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 2983-2989.	6.7	194
8	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. <i>Arthritis and Rheumatism</i> , 1998, 41, 670-677.	6.7	175
9	The Clinical Spectrum of the Eosinophilia-Myalgia Syndrome Associated with L-Tryptophan Ingestion. <i>Annals of Internal Medicine</i> , 1990, 113, 124.	2.0	147
10	A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2013, 15, R164.	1.6	100
11	MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 870-877.	6.7	98
12	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2372-2380.	6.7	96
13	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. <i>Arthritis and Rheumatism</i> , 2001, 44, 653-661.	6.7	96
14	Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11740-11745.	3.3	90
15	Providing information about options in patient decision aids. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, S4.	1.5	62
16	Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2011, 63, 373-382.	1.5	58
17	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 249-263.	1.6	49
18	Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. <i>Journal of Rheumatology</i> , 2008, 35, 618-24.	1.0	37

#	ARTICLE	IF	CITATIONS
19	An experimental evaluation of patient decision aid design to communicate the effects of medications on the rate of progression of structural joint damage in rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2012, 86, 329-334.	1.0	31
20	Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards. <i>Medical Decision Making</i> , 2021, 41, 780-800.	1.2	28
21	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. <i>Journal of Rheumatology</i> , 2015, 42, 2442-2447.	1.0	22
22	Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, 89.	1.5	20
23	Eosinophilic Fasciitis Associated With Use of L-Tryptophan: A Case-Control Study and Comparison of Clinical and Histopathologic Features. <i>Mayo Clinic Proceedings</i> , 1991, 66, 892-898.	1.4	18
24	Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2016, 197, 2854-2863.	0.4	18
25	Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Therapy in Rheumatoid Arthritis. <i>Medical Decision Making</i> , 2017, 37, 577-588.	1.2	9
26	Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	2.9	9
27	Communicating the Risk of Side Effects to Rheumatic Patients. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 653-662.	0.8	4